



Products

API's	Category	Specifications	Regulatory Status
Atenolol	Anti-Hypertensive	IP/BP/EP/USP	CEP, EU GMP, USDMF
Amlodipine Besylate	Anti-Hypertensive	IP/BP/EP/USP	DMF Available
Metoprolol Succinate	Anti-Hypertensive	IP/BP/EP/USP	DMF Available, USDMF filed
Metoprolol Tartrate	Anti-Hypertensive	IP/BP/EP/USP	DMF Available, USDMF filed
Roxithromycin	Macrolides	IP/BP/EP	CEP
Azithromycin	Macrolides	IP/BP/EP/USP	CEP, USDMF filed
Clarithromycin Granules 27.5%	Macrolides	In-House	DMF Available
Clarithromycin Granules 33%	Macrolides	In-House	
Clarithromycin Granules 43%	Macrolides	In-House	DMF Available
Pregabalin	Neuromodulator	IP/EP/In-House	CEP, USDMF filed
Ceftriaxone Sodium	Sterile Cephalosporins	IP/BP/EP/USP	DMF Available
Cefotaxime Sodium	Sterile Cephalosporins	IP/BP/EP/USP	DMF Available
Cefepime (with L-Arginine) for Injection	Sterile Cephalosporins	IP/USP	
Meropenem (with Sodium Carbonate) for Injection	Carbapenems	IP/USP	DMF Available
Doripenem	Carbapenems	In-House	DMF Available
Biapenem	Carbapenems	In-House	DMF Available
Lymecycline	Anti-Acne, Anti-Infective	EP	DMF Available, CEP filed
Nitroxoline	Antibiotic	In-House	DMF Available
Ticagrelor	Anti-Thrombotic	IP/EP/USP/In-House	DMF under preparation
Rivaroxaban	Anti-Thrombotic	IP/EP/USP/In-House	DMF under preparation
Apixaban	Anti-Thrombotic	In-House	DMF under preparation
Empagliflozin	Anti- Diabetic	In-House	DMF under preparation

Note : Products will not be offered for sale in countries where valid patents are in force. It is the responsibility of the Buyer to comply with the above.



Kopran

Pellets

Pellets	Category
Duloxetine Pellets 17%, 21.5%	Anti-Depressant
Venlafaxine Pellets 33%	Anti-Depressant
Dexlansoprazole Pellets 20%, 23%	Proton pump inhibitor

Products under development

API's	Category	R&D Sample availability	R&D Tech pack availability	Specification	RA Status
Dapagliflozin	Anti-Diabetic	Available	Under Lab Development	In-House	DMF will be available by Feb'23
Canagliflozin	Anti-Diabetic	Available	Under Lab Development	In-House	DMF will be available by Apr'23
Faropenem	Carbapenems	Available	Available	In-House	DMF will be available by Mar'23
Tebipenem	Carbapenems	Available	Available	In-House	DMF will be available by June'23
Ertapenem	Carbapenems	Nov.2021	Under Lab Development	In-House	DMF will be available by May'23
Imipenem (Non-Sterile)	Carbapenems	Dec.2021	Under Lab Development	USP	DMF will be available by Sep'23

**Note: Products will not be offered for sale in countries where valid patents are in force.
It is the responsibility of the Buyer to comply with the above.**